Summary
Eli Lilly and Company's 2019 10-K filing highlights a year of significant strategic moves and financial performance, including the substantial gain from the disposition of its remaining stake in Elanco Animal Health. The company reported increased revenue driven by volume growth in key products like Trulicity, Taltz, and Jardiance, alongside new product launches such as Baqsimi and Reyvow. Despite these positive developments, Lilly continues to navigate the challenges posed by patent expirations for older products like Forteo and Cialis, which have led to significant revenue erosion due to generic competition. The company's robust R&D pipeline remains a core focus, with significant investments in potential therapies for oncology, diabetes, neurodegeneration, immunology, and pain. The acquisition of Loxo Oncology in early 2019 for $6.9 billion bolstered Lilly's oncology pipeline, notably with selpercatinib. Looking ahead, Lilly announced an agreement to acquire Dermira, Inc. for approximately $1.1 billion, further strengthening its immunology portfolio. The company also provided financial guidance for 2020, anticipating continued revenue growth driven by its newer products.
Financial Highlights
53 data points| Revenue | $22.32B |
| Cost of Revenue | $4.72B |
| Gross Profit | $17.60B |
| R&D Expenses | $5.59B |
| SG&A Expenses | $6.21B |
| Interest Expense | $400.60M |
| Net Income | $8.32B |
| EPS (Basic) | $8.93 |
| EPS (Diluted) | $8.89 |
| Shares Outstanding (Basic) | 931.06M |
| Shares Outstanding (Diluted) | 935.68M |
Key Highlights
- 1Significant gain recognized from the disposition of the remaining Elanco Animal Health stake, boosting net income and EPS.
- 2Revenue increased by 4% to $22.3 billion, driven by volume growth in key diabetes and immunology products like Trulicity, Jardiance, and Taltz.
- 3The company completed the acquisition of Loxo Oncology for $6.9 billion, strengthening its oncology pipeline with promising assets like selpercatinib.
- 4New product launches, including Baqsimi for diabetes and Reyvow for migraine, contributed to revenue growth.
- 5Challenges remain with patent expirations for products like Forteo and Cialis, leading to significant revenue declines due to generic competition.
- 6Research and development expenses increased by 11% to $5.6 billion, reflecting continued investment in a robust pipeline for areas like oncology, diabetes, and immunology.
- 7Eli Lilly announced an agreement to acquire Dermira, Inc. for approximately $1.1 billion to expand its immunology pipeline.